DE60211746D1 - Aminosäurederivate zur behandlung der alzheimer-krankheit - Google Patents

Aminosäurederivate zur behandlung der alzheimer-krankheit

Info

Publication number
DE60211746D1
DE60211746D1 DE60211746T DE60211746T DE60211746D1 DE 60211746 D1 DE60211746 D1 DE 60211746D1 DE 60211746 T DE60211746 T DE 60211746T DE 60211746 T DE60211746 T DE 60211746T DE 60211746 D1 DE60211746 D1 DE 60211746D1
Authority
DE
Germany
Prior art keywords
sub
treatment
amino acid
acid derivatives
alzheimer disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60211746T
Other languages
English (en)
Inventor
Varghese John
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Pharmacia and Upjohn Co LLC
Original Assignee
Elan Pharmaceuticals LLC
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC, Pharmacia and Upjohn Co LLC filed Critical Elan Pharmaceuticals LLC
Application granted granted Critical
Publication of DE60211746D1 publication Critical patent/DE60211746D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE60211746T 2001-11-21 2002-11-21 Aminosäurederivate zur behandlung der alzheimer-krankheit Expired - Lifetime DE60211746D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33469201P 2001-11-21 2001-11-21
PCT/US2002/037360 WO2003045378A1 (en) 2001-11-21 2002-11-21 Amino acid derivatives useful for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
DE60211746D1 true DE60211746D1 (de) 2006-06-29

Family

ID=23308367

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60211746T Expired - Lifetime DE60211746D1 (de) 2001-11-21 2002-11-21 Aminosäurederivate zur behandlung der alzheimer-krankheit

Country Status (10)

Country Link
US (1) US20060079550A1 (de)
EP (1) EP1458378B1 (de)
JP (1) JP2005514370A (de)
AT (1) ATE326964T1 (de)
AU (1) AU2002356991A1 (de)
BR (1) BR0214359A (de)
CA (1) CA2477585A1 (de)
DE (1) DE60211746D1 (de)
MX (1) MXPA04004903A (de)
WO (1) WO2003045378A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162498A0 (en) * 2001-12-20 2005-11-20 Bristol Myers Squibb Co (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
JP2007502278A (ja) * 2003-08-14 2007-02-08 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のための大員環β−セクレターゼ阻害剤
CN1859904A (zh) * 2003-10-03 2006-11-08 默克公司 用于治疗阿尔茨海默氏病的苄醚和苄氨基β－分泌酶抑制剂
US7208488B2 (en) * 2003-10-29 2007-04-24 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
CA2546142A1 (en) * 2003-11-24 2005-06-09 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
CA2604291A1 (en) 2005-04-08 2006-10-19 Comentis, Inc. Compounds which inhibit beta-secretase activity and methods of use thereof
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US8637575B2 (en) 2008-06-05 2014-01-28 Novotyr Therapeutics Ltd. Modulators of protein kinase signaling
CN103242200A (zh) * 2013-04-10 2013-08-14 吉尔生化（上海）有限公司 一种Nα-芴甲氧羰基-Nε-乙酰基-赖氨酸的制备方法
WO2015008206A1 (en) 2013-07-14 2015-01-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
EP3253733B1 (de) 2015-02-05 2020-04-29 TyrNovo Ltd. Kombinationen von irs/stat3-doppelmodulatoren und antikrebsmittel zur behandlung von krebs
CN109265371A (zh) * 2018-10-12 2019-01-25 吉尔生化（上海）有限公司 一种Nα-[(9H-芴-9-基甲氧基)羰基]-Nε-乙酰基-L-赖氨酸的制备方法
CN109824547A (zh) * 2019-03-20 2019-05-31 康化（上海）新药研发有限公司 一种双不同保护氨基酸的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5986102A (en) * 1998-04-29 1999-11-16 Pharmacopeia, Inc. Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
CN1502692A (zh) * 1998-09-24 2004-06-09 �������Ŷ���Լ��������˾ 阿尔茨海默氏疾病分泌酶
US6455587B1 (en) * 2000-03-15 2002-09-24 Pharmacor Inc. Amino acid derivatives as HIV aspartyl protease inhibitors

Also Published As

Publication number Publication date
MXPA04004903A (es) 2005-06-06
US20060079550A1 (en) 2006-04-13
WO2003045378A1 (en) 2003-06-05
AU2002356991A1 (en) 2003-06-10
JP2005514370A (ja) 2005-05-19
ATE326964T1 (de) 2006-06-15
BR0214359A (pt) 2004-10-13
CA2477585A1 (en) 2003-06-05
EP1458378A1 (de) 2004-09-22
EP1458378B1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
MXPA05011150A (es) 2-hidroxi-3-diaminoalcanos de benzamida.
MXPA04003245A (es) Hidroxipropilaminas.
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
WO2003103653A8 (en) METHODS OF TREATING ALZHEIMER'S DISEASE WITH ALKANOIC ARYL ACID AMIDES
ATE326964T1 (de) Aminosäurederivate zur behandlung der alzheimer- krankheit
WO2003057721A3 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
UA84407C2 (en) Acetyl 2-hydroxy-1,3 diaminoalkanes
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
MXPA05011203A (es) Fenacil-2-hidroxi-3-diaminoalcanos.
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
WO2003030886A3 (en) Allylamides useful in the treatment of alzheimer's disease
DE60210614D1 (de) Für die behandlung von alzheimer krankheit geeignete makrocyclen
BR0213743A (pt) Métodos de tratar ou prevenir mal de alzheimer e uma doença, de tratar um indivìduo que tenha, ou de prevenir que um indivìduo contraia, uma doença ou condição, de inibir a atividade de beta-secretase, a clivagem de um isótipo de protéina precursora de amilóide e a produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase, uso de um composto e composição
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
MXPA04000337A (es) Amindioles para tratamiento de enfermedad de alzheimer.
MXPA03011399A (es) Metodos para tratar la enfermedad de alzheimer.
ATE359995T1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
WO2004029019A8 (en) Compounds for the treatment of alzheimer’s disease

Legal Events

Date Code Title Description
8332 No legal effect for de